Covered recipient · General Payments record
DAVID RP ALMEIDA
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$186,737.63
113 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $82,268.82 | 27 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,836.00 | 15 |
| Travel and Lodging | $30,574.36 | 38 |
| Honoraria | $7,000.00 | 2 |
| Food and Beverage | $3,058.45 | 31 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $31,527.47 | 13 |
| Dutch Ophthalmic, USA | $27,701.17 | 15 |
| Astellas Pharma US Inc | $21,001.93 | 12 |
| Genentech USA, Inc. | $20,521.63 | 17 |
| F. Hoffmann-La Roche AG | $20,281.20 | 6 |
| Hoffmann-La Roche Limited | $20,091.67 | 6 |
| Alcon Vision LLC | $19,247.06 | 13 |
| Alimera Sciences, Inc. | $9,423.49 | 11 |
| Boehringer Ingelheim International GmbH | $5,225.00 | 5 |
| Carl Zeiss Meditec, Inc. | $4,875.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,750.00 | 1 |
| Alcon Research LLC | $1,351.00 | 2 |
| Dutch Ophthalmic Research Center (International) B.V. | $318.32 | 5 |
| VisionCare Inc. | $204.74 | 2 |
| Mallinckrodt Hospital Products Inc. | $99.99 | 1 |
| Regeneron Pharmaceuticals, Inc. | $77.78 | 1 |
| AbbVie Inc. | $40.18 | 1 |
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID RP ALMEIDA
NPI 1437590718 · CMS profile ID 631878
Allopathic & Osteopathic Physicians / Ophthalmology
ERIE, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- DAVID RP ALMEIDA, NPI 1437590718, CMS profile ID 631878, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1437590718?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
113 matching records · $186,737.63 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–113 of 113.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche AG | $701.53 | 01/30/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345079 | CMS |
| F. Hoffmann-La Roche AG | $50.03 | 01/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345085 | CMS |
| Hoffmann-La Roche Limited | $9,240.00 | 01/26/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345091 | CMS |
| Hoffmann-La Roche Limited | $406.77 | 01/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345099 | CMS |
| Hoffmann-La Roche Limited | $22.77 | 01/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345105 | CMS |
| Hoffmann-La Roche Limited | $884.31 | 01/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040345111 | CMS |
| Carl Zeiss Meditec, Inc. | $975.00 | 01/23/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059458895 | CMS |
| Dutch Ophthalmic Research Center (International) B.V. | $27.02 | 01/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060585427 | CMS |
| Dutch Ophthalmic Research Center (International) B.V. | $41.07 | 01/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060585431 | CMS |
| Dutch Ophthalmic Research Center (International) B.V. | $162.14 | 01/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060585435 | CMS |
| Dutch Ophthalmic Research Center (International) B.V. | $50.26 | 01/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060585439 | CMS |
| Dutch Ophthalmic Research Center (International) B.V. | $37.83 | 01/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060585423 | CMS |
| Dutch Ophthalmic, USA | $7,441.55 | 01/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050671837 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $11,328.68 | 1 |
| PY2025 | Principal investigator | $1,572,271.86 | 430 |
| PY2024 | Recipient | $23,891.40 | 6 |
| PY2024 | Principal investigator | $1,357,830.89 | 181 |
| PY2023 | Recipient | $66,018.96 | 1 |
| PY2023 | Principal investigator | $1,639,504.79 | 98 |
| PY2022 | Principal investigator | $509,331.30 | 14 |
| PY2021 | Principal investigator | $518,433.81 | 10 |
| PY2020 | Principal investigator | $16,669.14 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
431 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Roche TCRC, Inc. | $23,617.00 | 12/31/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211595695 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,139.10 | 12/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 12/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1175418126 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,642.80 | 12/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233609 |
| Principal investigator 1 | ARGENX US, INC. | $3,633.46 | 12/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149909 |
| Principal investigator 1 | Genentech, Inc. | $63,891.00 | 12/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211603974 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,418.20 | 12/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184278024 |
| Principal investigator 1 | Astellas Pharma Global Development | $900.00 | 12/18/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182941 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,000.00 | 12/18/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182947 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 12/18/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211595692 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,250.00 | 12/17/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211664299 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,050.00 | 12/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418096 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,700.00 | 12/15/2025 | Non-covered Recipient Entity Eerie Retina Research | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233258 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 12/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184275489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 12/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184275491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 12/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184275493 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,244.80 | 12/12/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233605 |
| Principal investigator 1 | ARGENX US, INC. | $27,841.70 | 12/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149885 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $18,328.00 | 12/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211604012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $103.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $107.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $137.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $383.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,215.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $205.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $228.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $383.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $233.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $103.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $137.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $233.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $103.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,215.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $137.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $107.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $233.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $103.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $137.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $233.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,215.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $205.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $228.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,215.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $205.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $228.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $383.60 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.40 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $205.80 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $228.20 | 12/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184268611 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 12/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149859 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 12/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149862 |
| Principal investigator 1 | ARGENX US, INC. | $2,026.89 | 11/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149898 |
| Principal investigator 1 | ARGENX US, INC. | $5,303.14 | 11/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149901 |
| Principal investigator 1 | ARGENX US, INC. | $1,528.94 | 11/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149906 |
| Principal investigator 1 | Astellas Pharma Global Development | $573.00 | 11/24/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182943 |
| Principal investigator 1 | Astellas Pharma Global Development | $573.00 | 11/24/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182949 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $17,370.00 | 11/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233602 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603841 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603846 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603849 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603853 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603858 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 11/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603861 |
| Principal investigator 1 | Genentech, Inc. | $6,468.00 | 11/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211603967 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,285.60 | 11/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,603.32 | 11/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261807 |
| Principal investigator 1 | ABBVIE INC. | $20,280.00 | 11/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | No dispute reported | 06/30/2026 | 1202522903 |
| Principal investigator 1 | Genentech, Inc. | $210.00 | 11/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211603963 |
| Principal investigator 1 | Genentech, Inc. | $117,381.00 | 11/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603971 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,358.00 | 11/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211604003 |
| Principal investigator 1 | ABBVIE INC. | $4,115.49 | 11/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) | No dispute reported | 06/30/2026 | 1202520065 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $47,996.00 | 11/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211604008 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,348.00 | 11/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175418084 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 11/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149871 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 11/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149880 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,896.00 | 10/31/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233593 |
| Principal investigator 1 | ABBVIE INC. | $3,519.10 | 10/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | No dispute reported | 06/30/2026 | 1202519585 |
| Principal investigator 1 | ARGENX US, INC. | $2,651.57 | 10/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149893 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $44,314.20 | 10/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233590 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,648.00 | 10/27/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175418088 |
| Principal investigator 1 | Amgen Inc. | $25,200.00 | 10/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC DAVID ALMEIDA | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246641283 |
| Principal investigator 1 | ARGENX US, INC. | $23,787.45 | 10/23/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149890 |
| Principal investigator 1 | ARGENX US, INC. | $1,220.35 | 10/23/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149913 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $570.00 | 10/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233585 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,065.00 | 10/17/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,418.20 | 10/17/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184251187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,418.20 | 10/17/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184251189 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,400.00 | 10/15/2025 | Non-covered Recipient Entity Eerie Retina Research | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233254 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233619 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603723 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603732 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603740 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,137.40 | 10/08/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233575 |
| Principal investigator 1 | Roche TCRC, Inc. | $23,538.00 | 10/07/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211595687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,813.00 | 10/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175418102 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 10/02/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182945 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603628 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603631 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603635 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603639 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603643 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603647 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603651 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603656 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603660 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603664 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603668 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603672 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603677 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603681 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603685 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603688 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603693 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603696 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603700 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603703 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603707 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603711 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603715 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603719 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603728 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603736 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603743 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603749 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603754 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603758 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603762 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $317.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603767 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603771 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603775 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603778 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603782 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603785 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603789 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603793 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603796 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603801 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603805 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603810 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,376.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603814 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603819 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603824 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603828 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603832 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $338.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603837 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,242.00 | 10/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418077 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 10/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149866 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 10/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149876 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $11,691.90 | 10/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233567 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,110.00 | 10/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233571 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,446.00 | 09/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603981 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,513.00 | 09/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603994 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,207.00 | 09/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603999 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $570.00 | 09/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233563 |
| Principal investigator 1 | ARGENX US, INC. | $1,220.35 | 09/18/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149916 |
| Principal investigator 1 | ARGENX US, INC. | $9,398.09 | 09/18/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149919 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 09/12/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664349 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $952.00 | 09/12/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,219.72 | 09/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184235913 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,275.00 | 09/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233548 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,781.20 | 09/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233552 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,420.00 | 09/10/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $920.00 | 09/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418173 |
| Principal investigator 1 | Amgen Inc. | $27,375.00 | 09/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneous Teprotumumab in Participants with Active Moderate-to-Severe Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246641285 |
| Principal investigator 1 | Genentech, Inc. | $17,089.00 | 09/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603911 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,224.00 | 09/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233544 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 09/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149836 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 09/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149855 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $850.00 | 08/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233534 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,675.60 | 08/29/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,854.65 | 08/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418144 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,418.20 | 08/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184232133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 08/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184232135 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 08/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184232137 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $679.00 | 08/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184232139 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603580 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603583 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603600 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603612 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603617 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603620 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 08/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603624 |
| Principal investigator 1 | ARGENX US, INC. | $30,824.33 | 08/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149923 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,356.00 | 08/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418061 |
| Principal investigator 1 | Genentech, Inc. | $177.00 | 08/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603897 |
| Principal investigator 1 | Genentech, Inc. | $15,517.00 | 08/15/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603955 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182923 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182925 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182929 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182931 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182933 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182935 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182937 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,731.00 | 08/14/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182939 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,831.20 | 08/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233526 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $645.00 | 08/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233530 |
| Principal investigator 1 | Astellas Pharma Global Development | $13,000.00 | 08/11/2025 | Non-covered Recipient Entity Erie Retina Research LLC | A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration | No dispute reported | 06/30/2026 | 1234182927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,600.00 | 08/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418073 |
| Principal investigator 1 | ABBVIE INC. | $11,299.49 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | No dispute reported | 06/30/2026 | 1202503595 |
| Principal investigator 1 | Genentech, Inc. | $177.00 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603922 |
| Principal investigator 1 | Genentech, Inc. | $7,229.00 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603933 |
| Principal investigator 1 | Genentech, Inc. | $11,508.00 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603937 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $21,468.60 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233518 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,376.60 | 08/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233522 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 08/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149839 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 08/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149843 |
| Principal investigator 1 | Genentech, Inc. | $26,571.00 | 08/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603926 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $4,482.30 | 07/31/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567353 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,120.50 | 07/31/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567557 |
| Principal investigator 1 | Janssen Research & Development, LLC | $930.00 | 07/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175418113 |
| Principal investigator 1 | Genentech, Inc. | $1,133.00 | 07/25/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,400.00 | 07/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418161 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,212.80 | 07/25/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $679.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $98.00 | 07/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184218489 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,120.60 | 07/22/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567361 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,120.60 | 07/22/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567375 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,121.02 | 07/22/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567421 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $2,241.10 | 07/22/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567477 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,120.60 | 07/22/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567527 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 07/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603587 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 07/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603591 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 07/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603596 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 07/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603604 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 07/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211603608 |
| Principal investigator 1 | Genentech, Inc. | $5,736.00 | 07/18/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664362 |
| Principal investigator 1 | Genentech, Inc. | $444.00 | 07/16/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664367 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $795.00 | 07/16/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 07/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214928 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 07/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214930 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 07/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214932 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.00 | 07/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214934 |
| Principal investigator 1 | Genentech, Inc. | $3,016.00 | 07/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603906 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 07/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603918 |
| Principal investigator 1 | Genentech, Inc. | $9,923.00 | 07/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603942 |
| Principal investigator 1 | Genentech, Inc. | $2,646.00 | 07/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211603959 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,082.00 | 07/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233504 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,313.92 | 07/09/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213417 |
| Principal investigator 1 | Roche TCRC, Inc. | $13,467.70 | 07/08/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211595684 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,162.00 | 07/04/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233500 |
| Principal investigator 1 | Genentech, Inc. | $3,779.00 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603902 |
| Principal investigator 1 | Genentech, Inc. | $1,763.00 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603915 |
| Principal investigator 1 | Genentech, Inc. | $10,769.00 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603929 |
| Principal investigator 1 | Genentech, Inc. | $3,024.00 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603947 |
| Principal investigator 1 | Genentech, Inc. | $1,988.00 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603951 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,764.40 | 07/02/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233496 |
| Principal investigator 1 | ARGENX US, INC. | $441.00 | 07/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149847 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 07/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149851 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $13,525.50 | 07/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603977 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,500.00 | 07/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603986 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,544.00 | 07/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled | No dispute reported | 06/30/2026 | 1211603990 |
| Recipient | Ocular Therapeutix, Inc. | $11,328.68 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229227 |
| Principal investigator 1 | Roche TCRC, Inc. | $224.57 | 06/30/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211595680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,380.72 | 06/27/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,579.52 | 06/27/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,192.60 | 06/27/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184210974 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184210976 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211000 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211004 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211028 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211032 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211044 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211046 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211056 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 06/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184211553 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,264.65 | 06/09/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,568.00 | 06/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418179 |
| Principal investigator 1 | ARGENX US, INC. | $161.70 | 06/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149826 |
| Principal investigator 1 | ARGENX US, INC. | $13.40 | 06/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149829 |
| Principal investigator 1 | ARGENX US, INC. | $19.43 | 06/01/2025 | Non-covered Recipient Entity Erie Retina Research | A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1237149833 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $20,350.80 | 05/30/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233468 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,264.10 | 05/30/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233472 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $12,088.80 | 05/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233465 |
| Principal investigator 1 | Amgen Inc. | $4,738.49 | 05/27/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246641287 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,248.00 | 05/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233462 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $25,296.70 | 05/15/2025 | Non-covered Recipient Entity GREAT LAKES MEDICAL RESEARCH LLC | New Day Study | No dispute reported | 06/30/2026 | 1248567521 |
| Principal investigator 1 | Genentech, Inc. | $316.00 | 05/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603882 |
| Principal investigator 1 | Roche TCRC, Inc. | $42,656.00 | 05/13/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211595676 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $825.00 | 05/09/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233458 |
| Principal investigator 1 | Genentech, Inc. | $187.00 | 05/01/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664333 |
| Principal investigator 1 | Genentech, Inc. | $2,948.40 | 05/01/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664337 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,675.60 | 04/30/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233453 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,250.00 | 04/29/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211595672 |
| Principal investigator 1 | Genentech, Inc. | $6,504.00 | 04/23/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.00 | 04/17/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,466.00 | 04/11/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418067 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,031.00 | 04/08/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211664294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 04/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 04/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181874 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 04/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181876 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 04/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 04/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184181880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180474 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180476 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180478 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180480 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180482 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $94.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180484 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180486 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $340.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180488 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180490 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180492 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $120.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $384.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180496 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $169.00 | 04/01/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184180498 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,776.00 | 03/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418119 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $19,726.20 | 03/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233493 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $18,154.55 | 03/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233489 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $900.00 | 03/14/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233484 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,473.00 | 03/07/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,076.00 | 03/06/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418167 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $55,648.80 | 03/05/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233477 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,825.95 | 03/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418042 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,076.00 | 03/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418137 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,513.40 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,500.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155706 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155708 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155712 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155714 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,838.00 | 02/26/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184155716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,978.00 | 02/21/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418132 |
| Principal investigator 1 | Amgen Inc. | $22,350.00 | 02/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease | No dispute reported | 06/30/2026 | 1246641289 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595559 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595563 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595566 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595570 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595573 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595577 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595581 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595585 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595589 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595594 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595597 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595602 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595605 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595610 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595614 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595618 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595623 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595628 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595632 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595636 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595640 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595644 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595650 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595656 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595660 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $281.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595663 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $110.00 | 02/19/2025 | Non-covered Recipient Entity David Almeida D/B/A Erie Retina Research | REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER | No dispute reported | 06/30/2026 | 1211595668 |
| Principal investigator 1 | Genentech, Inc. | $875.00 | 02/19/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211603885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,076.00 | 02/17/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175418150 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,500.00 | 02/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184153890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,835.00 | 02/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184153892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,725.00 | 02/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184153894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 02/13/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184153896 |
| Principal investigator 1 | Genentech, Inc. | $13,616.00 | 02/12/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211603894 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,480.00 | 02/12/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233441 |
| Principal investigator 1 | Genentech, Inc. | $8,486.00 | 02/05/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664327 |
| Principal investigator 1 | Genentech, Inc. | $971.00 | 02/05/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211664330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,580.00 | 02/03/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418107 |
| Principal investigator 1 | Genentech, Inc. | $813.00 | 01/28/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211603890 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $22,053.60 | 01/24/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250233445 |
| Principal investigator 1 | Genentech, Inc. | $4,403.00 | 01/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603865 |
| Principal investigator 1 | Genentech, Inc. | $18,460.00 | 01/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603869 |
| Principal investigator 1 | Genentech, Inc. | $3,024.00 | 01/22/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH LLC | A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) | No dispute reported | 06/30/2026 | 1211603873 |
| Principal investigator 1 | Roche TCRC, Inc. | $7,872.00 | 01/21/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211664291 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,390.00 | 01/20/2025 | Non-covered Recipient Entity ERIE RETINA RESEARCH | A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants - No Compound | No dispute reported | 06/30/2026 | 1175418048 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,120.60 | 01/17/2025 | Non-covered Recipient Entity THE CLINICAL TRIALS NETWORK LLC | The SYNCHRONICITY Study | No dispute reported | 06/30/2026 | 1248567357 |